Prime Medicine (PRME) closed at $3.83 on Oct 19, 2026, up 10.4% on the day. The stock is up 22.8% over the past month, up 22.8% over three months, up 10.4% year to date and down 34.0% over the past year. It trades 31.9% below its 52-week high of $5.63 and 43.4% above its 52-week low of $2.67. The close sits above its 50-day moving average ($3.35) and above its 200-day moving average ($3.48).
NextPick tracks PRME in its Cell / Gene Therapy basket alongside CRSP, BEAM, VCEL, NTLA and EDIT. As of Oct 19, 2026, the basket's money-flow score is -18 (weak outflow), and the basket is down 4.8% over five sessions. Over the past month PRME ranks 1st of 7 basket members by price change.
Yes — the Oct 19, 2026 close of $3.83 is 10.1% above the 200-day average of $3.48.
PRME closed 31.9% below its 52-week high of $5.63.
NextPick groups PRME with CRSP, BEAM, VCEL, NTLA and EDIT in its Cell / Gene Therapy basket.
Prime Medicine, Inc., a biotechnology company, engages in delivering genetic medicines to address the spectrum of diseases by deploying gene editing technology in the United States. Its lead therapeutic product candidate is PM359 for Chronic Granulomatous Disease, which is in Phase 1/2 clinical trial; PM577 for Wilson Disease, that is in preclinical studies; and PM647 to treat genetic disorder caused by mutations in the SERPINA1 gene, resulting in production of misfolded Z-AAT protein that accumulates in the liver and leads to hepatocellular injury, cirrhosis, and increased risk of hepatocellular carcinoma. The company also provides vivo programs targeting diseases of the liver, and Cystic Fibrosis programs. In addition, it offers Prime Editing technology comprising a programmable DNA binding domains, such as Cas domains, are typically modified such that they do not cause a double-stranded break in the DNA, as well as a RT domain that copies the edited DNA sequence directly into the target genomic site where the edit is made; and pegRNA which contains a search sequence, also known as a spacer, which provides a target genomic address for the Prime Editor. The company has a research collaboration and license agreement with BMS; Cystic Fibrosis Foundation; Broad Institute; and Beam. Prime Medicine, Inc. was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.
